Studies On Synthesis And Technology Of RSR-13

There are a number of clinical conditions characterized by an insufficient oxygenation or hypoxia of the tissues. These induce tumor growth, ischemic coronary artery disease, cerebral ischemia and the management of patients during surgery and intensive care. The tissue hypoxia may be due to inadequate blood flow, inadequate hemoglobin function or increased tissue oxygen demand. Hemoglobin is an allosteric protein present in red blood cells that binds and transports oxygen. As an allosteric protein, hemoglobin exists in the equilibrium between an oxystate and a deoxy state. Compounds known as allosteric modifiers are able to shift this equilibrium. Thus, the compounds should be valuable as antischemic agents, as enhancers for x-ray radiation in cancer therapy, as antilipidemic agents in preparing blood substitutes and in blood storage.2-[-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxy]-2-methyl-propionic acid (RSR-13) is a new drug developed by Allos Therapeutics company of USA. It noncovalently binds in the central water cavity of the hemoglobin tetramer, reduing the hemoglobin oxygen affinity, and thereby enhancing the diffusion of oxygen to the tissues. It is useful in tumor-therapies as radiosensitizer, worthwhile for treatment of cardiac ischemia and cerebral ischemia. It is found to be the allosteric modifier of...